Insperity (NSP) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual Meeting scheduled for May 20, 2025, to vote on four key proposals, including director elections, executive compensation, an amendment to the incentive plan, and auditor ratification.
Board recommends voting in favor of all proposals; proxy materials and annual report are available to shareholders.
Shareholders of record as of April 4, 2025, are eligible to vote; multiple voting methods are available.
Voting matters and shareholder proposals
Four proposals: election of four Class III directors, advisory say-on-pay vote, approval of the First Amendment to the Incentive Plan, and ratification of Ernst & Young LLP as auditor.
Board recommends FOR all proposals; majority of votes cast required for approval.
Shareholder proposals and director nominations for 2026 require advance notice per bylaws.
Board of directors and corporate governance
Board consists of 11 members, with a mix of independent and non-independent directors; diversity in background and expertise is emphasized.
Lead independent director role established; three standing committees: Audit, Compensation, and Nominating & Governance.
Board and committees met regularly in 2024; all directors attended at least 75% of meetings.
Strict policies on hedging and pledging of company stock; code of conduct and annual compliance training in place.
Latest events from Insperity
- 2026 guidance targets margin recovery and growth, led by HRScale and cost controls.NSP
Q4 202513 Feb 2026 - Q2 2024 adjusted EPS up 34%, but 2024 guidance signals lower WSEEs and earnings.NSP
Q2 20242 Feb 2026 - Q3 net income and EPS dropped sharply, with full-year adjusted EPS guided at $3.42–$3.66.NSP
Q3 202417 Jan 2026 - Higher healthcare costs and economic uncertainty drove lower Q1 earnings despite revenue growth.NSP
Q1 202524 Dec 2025 - 2024 results showed resilient profitability, strong retention, and growth momentum for 2025.NSP
Q4 20249 Dec 2025 - Q3 revenue up 4% but net loss and EBITDA fell on higher costs; 2026 recovery expected.NSP
Q3 202513 Nov 2025 - Higher benefits costs drove Q2 profit declines, but 2026 profitability outlook remains strong.NSP
Q2 202531 Oct 2025